Subscribe To
ANTX / AN2 Therapeutics: Boron Chemistry For Infectious Diseases
ANTX News
By Business Wire
October 11, 2023
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatment more_horizontal
By Zacks Investment Research
September 11, 2023
Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year. more_horizontal
By Seeking Alpha
May 5, 2023
AN2 Therapeutics: Boron Chemistry For Infectious Diseases
AN2 is a developer of rare, infectious disease therapeutics. AN2 leverages its boron chemistry expertise and has a history of a successful sale to Pfi more_horizontal
By GlobeNewsWire
August 29, 2022
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on dev more_horizontal
By Benzinga
March 25, 2022
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15
AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' rais more_horizontal
By Barrons
March 21, 2022
AN2 Therapeutics Set for a March IPO
Biotech AN2 Therapeutics will be the second company to go public through a traditional initial public offering in March. more_horizontal